Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer

NCT00003327 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Cancer

Interventions

DRUG: paclitaxel

Sponsor

Theradex